Observes real-world care of people with advanced endometrial cancer receiving durvalumab
Collects data on durvalumab with chemotherapy and later maintenance in endometrial cancer.
Plain-language title generated from the registry record
Registry title: NIS to Examine the Effectiveness and Safety of Durvalumab and Olaparib in Patients With Endometrial Cancer (DUOLife)
Key facts
- Where
- Amberg, Bad Nauheim, Bautzen, Berlin, Bielefeld, Bonn, Borna, Bottrop, Brandenburg an der Havel, Braunschweig, Cologne, Dessau, Dresden, Ebersberg, Eggenfelden, Essen, Goslar, Greifswald, Gütersloh, Hamburg, Heilbronn, Homburg, Hösbach, Kiel, Krefeld, Kulmbach, Landshut, Leipzig, Limburg, Lüneburg, Magdeburg, Mainz, München, Neuruppin, Neuss, Nuremberg, Plauen, Rotenburg (Wümme), Siegen, Solingen, Stendal, Torgau, Traunstein, Unna, Wernigerode, Winnenden, Witten, Worms, and Zittau, GermanySee the 49 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 130 years old?
Source: NCT06890273, who can take part
Where in Germany
- AmbergAmberg, GermanyTaking people
- Bad NauheimBad Nauheim, GermanyTaking people
- BautzenBautzen, GermanyTaking people
- BerlinBerlin, GermanyTaking people
- BielefeldBielefeld, GermanyTaking people
- BonnBonn, GermanyTaking people
- BornaBorna, GermanyTaking people
- BottropBottrop, GermanyTaking people
- Brandenburg an der HavelBrandenburg an der Havel, GermanyTaking people
- BraunschweigBraunschweig, GermanyTaking people
- CologneCologne, GermanyTaking people
- DessauDessau, GermanyTaking people
- DresdenDresden, GermanyTaking people
- EbersbergEbersberg, GermanyTaking people
- EggenfeldenEggenfelden, GermanyTaking people
- EssenEssen, GermanyTaking people
- GoslarGoslar, GermanyTaking people
- GreifswaldGreifswald, GermanyTaking people
- GüterslohGütersloh, GermanyTaking people
- HamburgHamburg, GermanyTaking people
- HeilbronnHeilbronn, GermanyTaking people
- HomburgHomburg, GermanyTaking people
- HösbachHösbach, GermanyTaking people
- KielKiel, GermanyTaking people
- KrefeldKrefeld, GermanyTaking people
- KulmbachKulmbach, GermanyTaking people
- LandshutLandshut, GermanyTaking people
- LeipzigLeipzig, GermanyTaking people
- LimburgLimburg, GermanyTaking people
- LüneburgLüneburg, GermanyTaking people
- MagdeburgMagdeburg, GermanyTaking people
- MainzMainz, GermanyTaking people
- MünchenMünchen, GermanyTaking people
- NeuruppinNeuruppin, GermanyTaking people
- NeussNeuss, GermanyTaking people
- NurembergNuremberg, GermanyTaking people
- PlauenPlauen, GermanyTaking people
- Rotenburg (Wümme)Rotenburg (Wümme), GermanyTaking people
- SiegenSiegen, GermanyTaking people
- SolingenSolingen, GermanyTaking people
- StendalStendal, GermanyTaking people
- TorgauTorgau, GermanyTaking people
- TraunsteinTraunstein, GermanyTaking people
- UnnaUnna, GermanyTaking people
- WernigerodeWernigerode, GermanyTaking people
- WinnendenWinnenden, GermanyTaking people
- WittenWitten, GermanyTaking people
- WormsWorms, GermanyTaking people
- ZittauZittau, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06890273
- Record updated
- 30 September 2026
- Original description
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line (1L) regimens with Carboplatin/Paclitaxel/Durvalumab (CPD) followed by maintenance therapy with durvalumab or durvalumab and olaparib in line with the applicable european summary of product characteristics (SmPC). Additionally, patient-reported outcomes after 1L treatment with CPD will be assessed.Read full original descriptionShow less
Prospective NIS to Generate Real-World-Data on Effectiveness and Safety of First-line Therapy With Chemotherapy Combined With Durvalumab Followed by Maintenance Therapy With Durvalumab or Durvalumab + Olaparib in Endometrial Cancer
This is a German multi-center, prospective, non-interventional study (NIS) to collect real-world clinical data in patients with primary advanced (FIGO stage III or IV) or recurrent endometrial cancer (EC) receiving first-line (1L) regimens with Carboplatin/Paclitaxel/Durvalumab (CPD) followed by maintenance therapy with durvalumab or durvalumab and olaparib in line with the applicable european summary of product characteristics (SmPC). Additionally, patient-reported outcomes after 1L treatment with CPD will be assessed.
Inclusion: Women aged ≥ 18 years at the time of screening; Patient has pathologically documented:; Primary advanced (FIGO III and IV) epithelial EC OR; Recurrent disease that is unlikely to be cured and where the multidisciplinary tumor board decision is systemic therapy. Carcinosarcomas are allowed,; Patient is intended or initiated to receive 1L CPD followed by maintenance therapy with durvalumab (dMMR cohort) or with durvalumab and olaparib (pMMR cohort) according to the SmPC of IMFINZI® and Lynparza®* prior to enrollment. Recruitment of patients that already started and may have received up to 2 cycles of CPD is allowed but will be capped to 25% for each cohort of the study population; Patient is eligible for treatment with durvalumab and/or olaparib as specified in the IMFINZI® and Lynparza® SmPC. The prescription of the medicinal product is clearly separated from the decision to include the patient in the study; MMR-testing results of the patient's tumor are known; Patient is willing and able to complete PRO questionnaires; Patient can read and understand German, English, Arab, Russian or Turkish; Signed written informed consent.
Exclusion: Patient has already received >2 cycles of 1L CPD; Unable to swallow orally administered medication; Known hypersensitivity to carboplatin, paclitaxel, durvalumab and/or olaparib or any of the excipients of the drug; Pregnancy or breast-feeding; Current or planned participation in an interventional clinical trial; Current or planned systemic treatment of any tumor other than primary advanced or recurrent EC; Patient has pathologically documented sarcoma.